Losartan and SSRIs (Sertraline, Escitalopram): What Women Need to Know About This Drug Combination

The Short Answer: Can You Take Losartan With an SSRI?

Yes, most women can take losartan alongside sertraline or escitalopram, and clinicians prescribe this combination regularly. The interaction is real but is classified as minor-to-moderate in most drug interaction databases, not as a contraindication. What matters is knowing which risks to watch for, which women face higher risk, and how hormonal status changes the picture.

Losartan is an angiotensin II receptor blocker (ARB) used for hypertension, heart failure, and diabetic nephropathy. SSRIs, including sertraline and escitalopram, are first-line treatments for depression and anxiety and are also used off-label for premenstrual dysphoric disorder (PMDD), perimenopausal mood changes, and vasomotor symptoms. Many women end up on both drugs, and the overlap is not accidental.

How Each Drug Works: The Mechanisms That Create an Interaction

Understanding why an interaction can occur starts with understanding what each drug does on its own.

Losartan: Blocking Angiotensin II

Losartan blocks the AT1 receptor, preventing angiotensin II from constricting blood vessels and triggering aldosterone release. The result is vasodilation and modest sodium and water excretion. Losartan is converted to its active metabolite, EXP3174, primarily through CYP2C9 and to a lesser extent CYP3A4. Women have modestly lower CYP2C9 activity on average than men, a sex difference that can increase losartan exposure slightly, though the clinical magnitude is generally small.

SSRIs: Serotonin Reuptake and Beyond

Sertraline and escitalopram block the serotonin transporter (SERT), raising synaptic serotonin. They also inhibit certain CYP enzymes to varying degrees. Sertraline is a moderate inhibitor of CYP2C9 and CYP2D6. Escitalopram has a much cleaner CYP profile and inhibits CYP2D6 only modestly. Neither drug meaningfully inhibits CYP3A4 at typical clinical doses.

Where the Interaction Lives

The interaction between losartan and an SSRI is primarily pharmacodynamic, not pharmacokinetic. There are two main overlapping effects:

1. Blood pressure lowering. Both drug classes independently lower blood pressure. SSRIs can cause mild reductions in systolic blood pressure, particularly early in treatment, and the combination may produce additive hypotension.

2. Hyponatremia risk. SSRIs promote syndrome of inappropriate antidiuretic hormone (SIADH), which can lower serum sodium. Losartan's mild natriuretic effect (sodium excretion) could theoretically compound this. The risk is highest in older women, women on low-sodium diets, and those taking diuretics alongside either drug.

A third mechanism, serotonin syndrome, is theorized because angiotensin II may modulate serotonergic neurotransmission, but published case reports of frank serotonin syndrome attributable to losartan-plus-SSRI are exceedingly rare, and this risk should not be overstated.

The CYP2C9 Question: Does Sertraline Change Losartan Levels?

This is a reasonable concern. Sertraline is a moderate CYP2C9 inhibitor. Losartan's conversion to its active metabolite EXP3174 depends on CYP2C9. Theoretically, sertraline could reduce the formation of EXP3174, blunting losartan's antihypertensive effect.

In practice, the FDA losartan label does not list sertraline as a clinically significant inhibitor requiring dose adjustment. The interaction has not been studied head-to-head in a dedicated pharmacokinetic trial. What has been studied is fluconazole (a potent CYP2C9 inhibitor), which does increase losartan AUC substantially. Sertraline's inhibition is weaker than fluconazole's, so the effect on losartan exposure is likely modest.

The clinical implication: if you start sertraline while already stable on losartan, blood pressure should be rechecked within two to four weeks. A small rise in blood pressure could indicate reduced EXP3174 formation. Escitalopram does not inhibit CYP2C9 meaningfully and does not carry this concern.

A practical framework for the CYP2C9 concern by SSRI choice:

| SSRI | CYP2C9 Inhibition | Likely Effect on Losartan Levels | Action Needed | |---|---|---|---| | Sertraline | Moderate | May modestly reduce active metabolite | Recheck BP in 2-4 weeks | | Escitalopram | Negligible | Minimal | Routine monitoring | | Fluoxetine | Moderate (CYP2C9 and CYP2D6) | Similar to sertraline | Recheck BP in 2-4 weeks | | Paroxetine | Minimal CYP2C9 | Minimal | Routine monitoring |

Hyponatremia: The Risk Most Women Are Not Warned About

Low serum sodium from SSRI-induced SIADH is more common than most patients realize. A 2017 analysis in CNS Drugs found that SSRI-associated hyponatremia occurs in approximately 0.5 to 32 percent of patients depending on age, with older women carrying the highest risk. The wide range reflects variation by age and concomitant medications.

Losartan alone does not cause hyponatremia in most patients, but its renin-angiotensin blockade can blunt the compensatory mechanisms that maintain sodium balance when SIADH develops. The combination does not double the risk in a straightforward way, but it may make SIADH harder to compensate if it does occur.

Who Is at Highest Risk?

• Women over 65 years old
• Women on thiazide diuretics (hydrochlorothiazide is commonly combined with losartan as Hyzaar)
• Women with low body weight or malnutrition
• Women in the first four weeks of SSRI initiation (when SIADH is most likely to emerge)
• Women with hypothyroidism or adrenal insufficiency affecting sodium handling

Symptoms to Report Immediately

Headache, nausea, confusion, muscle cramps, or lethargy in the first month of adding either drug to a stable regimen warrant a serum sodium check. Do not dismiss these as typical SSRI start-up side effects without ruling out hyponatremia.

Hypotension and Dizziness: The More Common Day-to-Day Risk

Orthostatic hypotension (a drop in blood pressure on standing) is the most practically relevant interaction for most women on this combination. SSRIs lower standing systolic blood pressure by roughly 5 to 10 mmHg on average in the first weeks of treatment, added on top of whatever losartan is already contributing.

Dizziness on standing, lightheadedness, or fainting spells should be taken seriously and reported. Falls in older perimenopausal and postmenopausal women carry real consequences for bone health, particularly in women with osteoporosis or low bone density.

Practical advice: rise slowly from bed or a chair, stay hydrated, and avoid alcohol while adjusting to either drug.

Women-Specific Conditions That Bring These Drugs Together

PCOS (Polycystic Ovary Syndrome)

Women with PCOS have a prevalence of depression and anxiety approximately three times higher than women without PCOS, making SSRIs common in this population. PCOS also carries elevated risk of hypertension, insulin resistance, and early renal involvement, conditions where losartan is used both as a standard antihypertensive and, off-label, for renoprotection. The combination is therefore more likely in younger women with PCOS than in the general population, a group where pregnancy planning also becomes relevant (see the pregnancy section below).

Perimenopause and Postmenopause

This is the life stage where this combination is most frequently prescribed. Blood pressure rises after menopause, partly because estrogen's vasodilatory effect is lost. At the same time, depression, anxiety, and vasomotor symptoms peak in perimenopause, driving SSRI prescriptions. The Menopause Society (formerly NAMS) lists SSRIs, including escitalopram and sertraline, as effective non-hormonal treatments for vasomotor symptoms.

A woman in her late 40s or early 50s may be starting losartan for newly elevated blood pressure while simultaneously starting escitalopram for perimenopausal mood changes. Her clinician should set a blood pressure check at the two-week mark and ask about dizziness at every visit for the first two months.

Postpartum and Lactation Period

Depression is common postpartum, affecting approximately 10 to 15 percent of women in the first year after delivery. If a woman needs both an antidepressant and blood pressure control postpartum, the SSRI and antihypertensive selection must account for breastfeeding safety (see the section below).

Pregnancy, Lactation, and Contraception: A Required Section

This section applies to any woman of reproductive age taking either drug.

Losartan in Pregnancy: Contraindicated

Losartan carries an FDA black box warning for fetal toxicity. All ARBs and ACE inhibitors, when used in the second and third trimesters, can cause fetal renal dysplasia, oligohydramnios, neonatal renal failure, skull hypoplasia, and death. The black box language is explicit: "When pregnancy is detected, discontinue losartan as soon as possible." First-trimester exposure is not considered safe either, based on available data, though the teratogenic window is highest in the second and third trimesters.

Any woman of childbearing age on losartan who is not actively using reliable contraception should have a frank conversation with her prescriber about pregnancy risk and alternative antihypertensives (such as labetalol, nifedipine, or methyldopa) that have established safety data in pregnancy.

SSRIs in Pregnancy: Nuanced, Not Blanket-Contraindicated

Sertraline and escitalopram are classified as having available human pregnancy data and are among the most studied antidepressants in pregnancy. They are not teratogens in the classic sense. The primary concerns are:

• Persistent pulmonary hypertension of the newborn (PPHN): A 2006 NEJM study by Chambers et al. Found an approximately sixfold increased risk of PPHN in infants exposed to SSRIs after 20 weeks gestation, though absolute risk remains low.
• Neonatal adaptation syndrome: Third-trimester exposure may cause transient jitteriness, poor feeding, and irritability in the newborn, typically resolving within days.

The decision to continue or stop an SSRI during pregnancy must weigh the risks of untreated depression against fetal exposure risks. Abrupt discontinuation is rarely the safest choice. This is a conversation for a prescribing clinician, ideally an OB-GYN or maternal-fetal medicine specialist.

Lactation

Sertraline has the largest safety dataset for breastfeeding and is generally considered compatible with breastfeeding by LactMed; infant serum levels are typically undetectable or very low. Escitalopram also has a favorable lactation profile, with low relative infant dose.

Losartan transfer into breast milk is not well characterized in human data. LactMed categorizes the ARB class as probably compatible with breastfeeding but notes that data are limited, and some guidelines recommend using alternatives with better established safety data, such as nifedipine or enalapril, during lactation.

Who This Combination Is and Is Not Right For

Generally Appropriate (With Monitoring)

• Postmenopausal women with hypertension and comorbid depression or anxiety
• Perimenopausal women using sertraline or escitalopram for vasomotor symptoms or mood changes alongside antihypertensive therapy
• Women with PCOS who need both drugs, with close attention to contraception

Requires Extra Caution

• Women over 65, especially those also on thiazide diuretics, because of compounded hyponatremia and hypotension risk
• Women with chronic kidney disease, where both drug classes affect sodium and potassium handling
• Women on a low-sodium diet, as SIADH can tip into clinically significant hyponatremia more easily

Not Appropriate

• Women who are pregnant or trying to conceive (losartan is contraindicated; discuss switching)
• Women with a history of symptomatic SIADH on either drug individually

Monitoring Recommendations by Life Stage

Monitoring should not be one-size-fits-all. Here is how surveillance shifts across reproductive life stages.

Reproductive Years (Ages 18 to 45)

• Confirm reliable contraception at every visit if on losartan
• Blood pressure check two to four weeks after starting or changing either drug
• Serum sodium at baseline and at four weeks if on sertraline, particularly if a thiazide is also prescribed
• Ask about PMDD or cycle-related mood changes, as SSRIs may need dose adjustment perimenstrually in some women

Perimenopause (Roughly Ages 45 to 55)

• Blood pressure variability increases with hormonal flux; more frequent BP monitoring (monthly initially) is reasonable
• Counsel on orthostatic hypotension risk and fall prevention
• Screen for new or worsening mood symptoms at each visit, as perimenopausal depression can be underdiagnosed

Postmenopause (Ages 55 and Older)

• Serum sodium annually or if symptoms emerge
• Renal function (eGFR) and potassium annually on losartan
• Review the full medication list for other sodium-lowering agents (proton pump inhibitors, carbamazepine, and thiazides all compound hyponatremia risk)

Patient Counseling Points: What to Tell Your Prescriber and What to Watch For

Many women on multiple medications are managing their own care across several providers who may not be communicating with each other. These talking points help you advocate for yourself.

• Tell every prescribing provider you take losartan. Drug interaction checks often miss pharmacodynamic interactions that are not captured in simple CYP databases.
• If you start sertraline while on losartan, plan a blood pressure check at two weeks. A blood pressure that rises after starting sertraline could indicate reduced losartan effect through CYP2C9 inhibition.
• Dizziness on standing in the first month of any new drug is worth reporting, not waiting out.
• If you plan to become pregnant, losartan must be stopped before conception. Ask your provider about labetalol or extended-release nifedipine as pregnancy-safe alternatives. This conversation should happen well before you start trying.
• Alcohol amplifies both hypotension and sedation when you are taking an SSRI. The effect is real even with small amounts.

The FDA drug interaction guidance for losartan lists non-steroidal anti-inflammatory drugs (NSAIDs) as a more significant interaction than SSRIs, because NSAIDs blunt losartan's antihypertensive effect and increase renal risk. Women who take ibuprofen or naproxen regularly for menstrual pain while on losartan face a higher-priority interaction than the SSRI combination.

Evidence Gaps: What We Do Not Know

Women have historically been underrepresented in cardiovascular and pharmacokinetic trials. A 2020 review in Circulation found that women comprised only 38 percent of participants in major cardiovascular outcome trials published between 2010 and 2019. Losartan's landmark LIFE trial enrolled women but did not report sex-stratified CYP interaction data. There is no dedicated pharmacokinetic study of the losartan-sertraline interaction. Current guidance is extrapolated from individual drug labels, CYP enzyme inhibition studies, and case series, not from a prospective interaction trial in women.

This is a real gap. The clinical recommendations above are based on mechanistic reasoning and indirect evidence. If your situation is complex (kidney disease, multiple interacting medications, or unusual sodium levels), a clinical pharmacist review or a consult with a women's health specialist is appropriate.